N/A
N=60
ADHD Electrophysiological Subtypes and Implications in Transcranial Direct-current Stimulation
ADHD · ADD
Bottom Line
View on ClinicalTrials.gov: NCT01649232 ↗Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Apr 2014
Primary outcome: Primary: Clinical Assessment (Amen Questionnaire) — 9.85; 3.55; 5.15; 3.54 units on a scale
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Active tDCS (Device)
- Age
- Pediatric, Adult, Older Adult · 8+ yrs
- Sex
- All
- Sponsor
- Spanish Foundation for Neurometrics Development
- Primary completion
- Dec 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clinical Assessment (Amen Questionnaire) |
9.85; 3.55; 5.15; 3.54 | — |
| SECONDARY Event-related Potentials Amplitude (ERPs) |
6.07; 5.40; 4.96; 4.77; 9.22; 7.01 | — |
| SECONDARY Event-related Potentials Latency (ERPs) |
323.78; 324.44; 321.56; 326.21; 348.67; 354.00 | — |
| SECONDARY Reaction Time (Behavior Task) |
466.95; 354.68; 444.65; 356.58; 467.04; 352.29 | — |
| SECONDARY Number of Omission and Commission Errors of Behavior Task |
11.22; 1.07; 12.22; 1.04; 0.83; 0.04 | — |
Summary
In the present study the aim is to examine whether transcranial direct-current stimulation (tDCS) generated excitability changes and induce modifications of functional cortical architecture in Attention Deficit Hyperactivity Disorder (ADHD) patients. To achieve this, the investigators used an event-related potential (ERP) analysis based on 20 channel EEG recordings in ADHD subjects before and after bipolar tDCS-anode stimulation over F3/F4 or T5/T6 or P4/P3, during resting state and measure clinical scores and visual CPT tasks changes. Time courses and topography of independent component visual ERPs were compared before and after tDCS.
Eligibility Criteria
Inclusion criteria
- ADHD diagnosis.
- Age between 7 and 65 years.
- Comorbidities were no reason for subject exclusion.
Exclusion criteria
- Presence of psychosis.
- Subjects taking medication, they had refrained from taking methylphenidate during 24 hours before testing.
- Subjects taking other psychotropics were not included in the study.
- Subjects which had suffered of a head injury with subsequent loss of consciousness, and subjects suffering from neurological or systemic medical diseases were excluded from the study.
Data sourced from ClinicalTrials.gov (NCT01649232). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.